IEQ Capital’s Moleculin Biotech MBRX Stock Holding History

IEQ Capital’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,455	Closed	-$19.3K	–	1940
2025 Q3	$19.3K	Buy	+1,455	New	+$19.7K	﹤0.01%	1824

Other funds holding MBRX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EFG International Zurich $4.67B AUM

PWPS

Pinnacle Wealth Planning Services Mansfield, Ohio $968M AUM 19.1% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

IEQ Capital's MBRX Position: Q4 2025 in Review

IEQ Capital sold out of Moleculin Biotech (MBRX) in Q4 2025, closing a stake of 1,455 shares — an estimated $19.3K sold.

IEQ Capital first reported a position in MBRX in Q3 2025 and held it in 1 quarter. The position peaked at $19.3K in Q3 2025. 17 funds tracked by Wall St. Rank hold MBRX as of Q4 2025.

IEQ Capital reported no remaining Moleculin Biotech position as of Q4 2025 after selling out during the quarter.
IEQ Capital sold 1,455 Moleculin Biotech shares in Q4 2025, an estimated $19.3K.
IEQ Capital first reported a position in Moleculin Biotech in Q3 2025 and held it in 1 quarter.
IEQ Capital's Moleculin Biotech position peaked at $19.3K in Q3 2025.
17 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2025.

Based on IEQ Capital's 13F filing for Q4 2025, filed 13 Feb 2026.